PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Mitochondrial and cellular

MOTS-c

Also written as: Mitochondrial open reading frame of the 12S rRNA type-c, MOTS-c (free base), MOTS-c acetate, MOTSc, MOTs-C, Mitochondrial-derived peptide MOTS-c

MOTS-c is a 16-amino-acid peptide that the body makes from a gene inside mitochondria; it improved blood sugar handling and exercise capacity in mice, but the United States Food and Drug Administration reported in 2026 that it found no human studies of MOTS-c at all.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • MOTS-c is a 16-amino-acid peptide your own mitochondria make. It is not an approved medicine anywhere.
  • In mice it reduced weight gain on a fatty diet, improved insulin sensitivity, and roughly doubled how long old animals could run on a treadmill.
  • In 2026 the FDA searched for human studies and found none: no one has been given MOTS-c in any published clinical study, by any route.
  • The human data that exist only measure the body's own MOTS-c in blood, and those studies disagree with each other.
  • The only finished randomised trial in this area tested CB4211, a company-made analogue of MOTS-c, not MOTS-c itself: 88 people took part, including 20 with fatty liver disease who had it or a placebo for four weeks, and the results were announced by the company, not published in a journal. A randomised trial of MOTS-c itself began in 2026 and has not reported.
  • Safety in people is unknown, and there are no animal studies of toxicity, genetic damage or cancer risk either.
  • It is banned in sport at all times, named by WADA as an AMPK activator.

What it is

MOTS-c is a peptide, which means a short chain of amino acids (the building blocks of proteins). It has 16 amino acids. It is unusual because the instructions for making it sit inside mitochondrial DNA. Mitochondria are the small compartments inside cells that turn food and oxygen into usable energy, and they carry their own small loop of DNA, separate from the DNA in the cell nucleus.

More on what it is and where it came from

Peptides written in mitochondrial DNA are called mitochondrial-derived peptides. MOTS-c was the second one described. Its name is short for 'mitochondrial open reading frame of the 12S rRNA type-c': an open reading frame is a stretch of genetic code that can be read as a recipe for a protein, and 12S rRNA is the mitochondrial gene that stretch sits inside. The discovering group reported that the recipe is only 51 letters of genetic code long.

MOTS-c is present naturally in human blood and muscle. The MOTS-c in research and in products sold online is a synthetic copy made in a laboratory. The FDA has pointed out that the plain peptide (the free base) and a salt form (the acetate) are different chemical ingredients sold under the same name. No medicine containing MOTS-c is approved anywhere; a 2026 FDA review found no monograph for it in the United States, European or Japanese pharmacopoeias and no product authorised by the European Medicines Agency.

MOTS-c was described in a paper published in Cell Metabolism on 3 March 2015 by Changhan Lee, Pinchas Cohen and colleagues, then at the University of Southern California and the University of California, Los Angeles, with co-authors including Rafael de Cabo at the United States National Institute on Aging. They were not isolating it from tissue: they searched the mitochondrial 12S rRNA gene by computer for short stretches that looked like they could be read as a protein, found one, made the peptide synthetically and then showed, using an antibody test they built, that it is present in the blood and tissues of humans and rodents. Pinchas Cohen later founded the company CohBar, which licensed this family of peptides from UCLA; in a 2021 announcement filed with the Securities and Exchange Commission, CohBar dated the discovery to 2012, three years before the paper.

How it is thought to work

The 2015 discovery paper proposed a chain of events that starts inside the cell. In human kidney cells grown in a dish, MOTS-c slowed down the folate cycle, a set of chemical steps cells use to build new DNA letters called purines. When those steps are blocked, a chemical called AICAR builds up, and AICAR switches on an enzyme called AMPK. AMPK acts roughly like a low-fuel warning light: when it is on, the cell burns more fat and sugar and stores less. In the discovery paper the build-up of AICAR in treated cells was more than twentyfold.

More on how it works

A 2018 paper from the same group reported that, when cells were starved of glucose, MOTS-c moved into the cell nucleus and attached to control switches on nuclear genes, working together with a stress protein called NRF2. If that is right, it means a peptide written in mitochondrial DNA can talk back to the cell's main genome. This has been shown in cells, not in people.

How well any of this applies to injected or swallowed MOTS-c in a person is unknown. In its 2026 review the FDA wrote that the molecular targets through which MOTS-c acts 'remain unknown', which makes it hard to predict which organs it would affect, and that the animal studies did not test whether larger amounts produced larger effects. The FDA also found no study measuring how MOTS-c is absorbed or cleared in any living body. The one relevant laboratory study it found, by a German anti-doping group, mixed MOTS-c with human blood in a test tube and watched it break apart quickly into shorter fragments.

What is established in people

Nothing is established in people. Searching in 2026, the FDA found no clinical study of any kind in which MOTS-c was given to a human being, by any route. What human data exist are observational: studies that measured the body's own MOTS-c in blood or muscle and compared groups. Those point in inconsistent directions, with a 2024 pooled analysis of 7 studies in 602 people finding lower levels in type 2 diabetes but higher levels in obesity, and one small study finding no difference at all; a laboratory group has also shown that the antibody tests used to produce these numbers disagree with mass spectrometry. A genetic variant that alters MOTS-c is linked to more type 2 diabetes in inactive Japanese men, which is suggestive but is not a treatment result. The only randomised, placebo-controlled human trial in this area tested CB4211, a company-made analogue, not MOTS-c; it enrolled 20 people with fatty liver for four weeks and its results were released by the company, not published. A first trial of MOTS-c itself, in 120 adults with prediabetes, was registered in China in 2026 and has no results.

What the studies found

14 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2026

    A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity (NCT07505745)

    If it is completed and published, this would be the first trial to give MOTS-c itself to people.

    Full finding, who was studied, and limits

    Who: A planned 120 adults aged 18 to 65 with prediabetes and a raised body mass index, split at random between MOTS-c and a matching dummy injection under the skin once a day for 12 weeks, with neither patients nor staff knowing which. One site, Peking University Shenzhen Hospital, China. Sponsor: Hudson Biotech.

    If it is completed and published, this would be the first trial to give MOTS-c itself to people. It was listed as recruiting, with a start date of 2 February 2026 and main results estimated for February 2027. No results exist yet.

    Read with care: A registration is a plan, not evidence. The record was last updated on 1 April 2026 and has one site. Registry entries are submitted by sponsors and are not independently checked.

    ClinicalTrials.gov · clinicaltrials.gov

  2. Human trial2024

    The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis.

    Taken together, blood MOTS-c was lower in people with diabetes or obesity than in comparison groups (standardised difference -0.37, 95% confidence interval -0.53 to -0.20).

    Full finding, who was studied, and limits

    Who: A pooled analysis of 6 case-control studies and 1 cross-sectional study, 602 people in total, searching six databases up to April 2023.

    Taken together, blood MOTS-c was lower in people with diabetes or obesity than in comparison groups (standardised difference -0.37, 95% confidence interval -0.53 to -0.20). Splitting the groups reversed part of the picture: in type 2 diabetes MOTS-c was clearly lower (-0.89, -1.12 to -0.65) while in obesity alone it was higher (0.51, 0.21 to 0.81). MOTS-c was weakly linked to higher total and LDL cholesterol.

    Read with care: All the included studies simply measured a peptide in blood at one moment; none gave anyone MOTS-c. Seven small studies totalling 602 people is a thin base, the obesity and diabetes results point in opposite directions, and different laboratories using different antibody tests do not agree on what a normal level is.

    Diabetology & Metabolic Syndrome · pmc.ncbi.nlm.nih.gov

  3. Human trial2021

    A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.

    About 5% to 8% of people of East Asian descent carry a change in mitochondrial DNA (m.1382A>C) that swaps one amino acid in MOTS-c.

    Full finding, who was studied, and limits

    Who: A combined analysis of three Japanese and Japanese-American population studies, 27,527 people in total, plus a separate group of 73 men whose blood was tested and groups of 8 to 12 mice.

    About 5% to 8% of people of East Asian descent carry a change in mitochondrial DNA (m.1382A>C) that swaps one amino acid in MOTS-c. Men carrying it had more type 2 diabetes than non-carriers (pooled Z = 2.86, P < 0.01); women did not (P = 0.64). In one study the difference appeared only among the least physically active third of men: 18.5% of carriers had diabetes versus 11.2% of non-carriers (P = 0.014). Carriers had nearly twentyfold higher MOTS-c in their blood. In mice, ordinary MOTS-c reduced weight gain and improved sugar handling but the altered version did not.

    Read with care: This is observational: it links a genetic variant to a disease, it does not show that giving MOTS-c prevents diabetes. The blood-level result rests on only 8 carriers, and the authors warn that their test measures the altered peptide less reliably. Participant numbers differ between sections of the paper. Physical activity was measured by questionnaire in two of the three studies. The senior author is a consultant and shareholder of CohBar.

    Aging (Albany NY) · pmc.ncbi.nlm.nih.gov

  4. Human trial2021

    A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (NCT03998514)

    CohBar announced on 10 August 2021 that the drug was 'well-tolerated and appeared safe with no serious adverse events', and that the only side effect affecting more than one in ten people was a temporary, mild to moderate reaction where the injection was given.

    Full finding, who was studied, and limits

    Who: NOT MOTS-c. CB4211 is a modified, laboratory-designed version of MOTS-c made by the company CohBar, which calls it 'a novel and improved analog of MOTS-c'. The trial enrolled 88 people in total: 65 healthy adults in the first part, and 20 adults with obesity and fatty liver disease in the second part, who received CB4211 (11 people) or a dummy injection (9 people) once a day under the skin for four weeks.

    CohBar announced on 10 August 2021 that the drug was 'well-tolerated and appeared safe with no serious adverse events', and that the only side effect affecting more than one in ten people was a temporary, mild to moderate reaction where the injection was given. It reported that two liver enzymes fell more than with placebo (ALT down 21% versus up 4%; AST down 28% versus down 11%) and blood sugar fell 6% more than placebo, each described as reaching statistical significance. Liver fat fell by about the same amount in both groups, and body weight showed only a 'trend'.

    Read with care: This is the strongest human safety information that exists in this area, and it is not about MOTS-c. An analogue is a different molecule designed to behave differently, chiefly to last longer in the body. The results come from a company press release, not a peer-reviewed paper; no results have been posted to the registry and I found no publication. Twenty people for four weeks cannot establish benefit, the liver-fat measurement showed no difference, and the company later wound down. The registry record was last updated in May 2021.

    ClinicalTrials.gov, with results given in a company announcement filed with the Securities and Exchange Commission · clinicaltrials.gov

  5. Human trial2020

    Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition.

    MOTS-c in blood fell with age, but MOTS-c in muscle went the other way: about 1.5 times higher in the middle-aged and older men than in the young men.

    Full finding, who was studied, and limits

    Who: Healthy men in three age bands: 18 to 30, 45 to 55, and 70 to 81 years.

    MOTS-c in blood fell with age, but MOTS-c in muscle went the other way: about 1.5 times higher in the middle-aged and older men than in the young men. Blood and muscle levels matched each other only in the young men. In the oldest men, more muscle MOTS-c went with better muscle quality, measured as leg-press strength relative to thigh size.

    Read with care: Observational, men only, modest numbers, and a snapshot rather than a follow-up over time. It complicates the simple claim that MOTS-c 'declines with age', since that depends on where you measure it.

    Aging (Albany NY) · pubmed.ncbi.nlm.nih.gov

  6. Human trial2019

    Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects.

    Blood MOTS-c rose sharply during the fat infusion, roughly two to threefold, and insulin blunted that rise.

    Full finding, who was studied, and limits

    Who: Women with polycystic ovary syndrome and healthy women, each given a fat infusion or salt water for five hours, with an insulin test in the final two hours, before and after an eight-week exercise programme.

    Blood MOTS-c rose sharply during the fat infusion, roughly two to threefold, and insulin blunted that rise. Eight weeks of moderate exercise training did not change resting MOTS-c levels in either group.

    Read with care: Small, women only, and the abstract does not give participant numbers. The 'no change after eight weeks of training' result sits awkwardly beside the single-session exercise rise seen in men, and the authors do not resolve that.

    Clinical Endocrinology · pubmed.ncbi.nlm.nih.gov

  7. Human trial2018

    Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance.

    Blood MOTS-c was lower in the group with obesity than in controls (P < 0.01).

    Full finding, who was studied, and limits

    Who: 40 children and adolescents with obesity (27 boys) and 57 controls (40 boys), recruited in Hubei Province, China, in 2017.

    Blood MOTS-c was lower in the group with obesity than in controls (P < 0.01). The difference was clear in boys (P < 0.001) but not in girls. In boys, lower MOTS-c went with higher body mass index, waist measurement, fasting insulin, insulin-resistance score and HbA1c.

    Read with care: A snapshot comparison, so it cannot show which came first. Small, single region, and the finding held only in boys. Nobody was treated with anything.

    Pediatric Diabetes · pubmed.ncbi.nlm.nih.gov

  8. Human trial2018

    Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals.

    Blood MOTS-c was essentially the same in the two groups (P = 0.60), even though the obese participants were measurably more insulin resistant.

    Full finding, who was studied, and limits

    Who: 10 lean and 10 obese adults.

    Blood MOTS-c was essentially the same in the two groups (P = 0.60), even though the obese participants were measurably more insulin resistant. Across everyone, higher MOTS-c went with more insulin resistance, not less, and that link held only within the lean group.

    Read with care: Twenty people. Included here because it points the opposite way to the obesity studies above and to the popular story that more MOTS-c means better metabolic health.

    Journal of Investigative Medicine · pubmed.ncbi.nlm.nih.gov

  9. Review2026

    Evaluation of MOTS-c-related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate) for Inclusion on the 503A Bulk Drug Substances List

    The FDA wrote that 'The nomination did not include, and FDA has not identified, any clinical studies or human exposure data for MOTS-c via any route of administration.

    Full finding, who was studied, and limits

    Who: FDA chemistry, pharmacology, toxicology and medical reviewers assessed all publicly available data on MOTS-c for the uses proposed to them: insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity.

    The FDA wrote that 'The nomination did not include, and FDA has not identified, any clinical studies or human exposure data for MOTS-c via any route of administration. Therefore, potential safety risks associated with the use of MOTS-c-related BDSs in humans are unknown.' It found no studies of acute toxicity, repeat-dose toxicity, genetic damage, effects on reproduction or development, or cancer risk, and no measurements of how the peptide behaves in any living body. It found no published report of MOTS-c being compounded for patients, and no reports in its own side-effect database. It concluded that the evidence 'weighs against' adding either form to the list of substances pharmacies may compound from.

    Read with care: This is a staff review written for an advisory meeting, not a final agency decision. The advisory committee later voted the other way, and the Department of Health and Human Services then took a different position. The FDA assessed only the uses it was asked about.

    FDA briefing document for the Pharmacy Compounding Advisory Committee, dated 11 May 2026 · fda.gov

  10. Animal study2021

    MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.

    Old treated mice ran about twice as long and about 2.16 times as far as untreated old mice, and 17% of them reached the final treadmill stage while none of the untreated ones did.

    Full finding, who was studied, and limits

    Who: Male mice of three ages (about 2, 12 and 22 months), treated daily for 2 weeks and then run on a treadmill: 10 middle-aged mice, 19 untreated old mice and 18 treated old mice, plus groups of 5 to 8 young mice on normal or high-fat diets. A separate group began intermittent treatment late in life, at 23.5 months. Also 10 healthy young men (average age about 24) who did a session of hard interval cycling.

    Old treated mice ran about twice as long and about 2.16 times as far as untreated old mice, and 17% of them reached the final treadmill stage while none of the untreated ones did. In the mice that started treatment at 23.5 months, grip strength, stride length and a 60-second walking test all improved. In the men, MOTS-c in muscle rose 11.9-fold immediately after exercise and blood levels rose about 1.5 to 1.6-fold, returning to normal after 4 hours of rest.

    Read with care: This is the study most often quoted as showing MOTS-c 'extends lifespan'. It does not. Median survival was 6.4% longer and maximum survival 7.0% longer in treated mice, but the survival curves were not statistically different overall (P = 0.23) and the authors themselves call it a trend needing larger groups. The human part of the study measured the body's own MOTS-c after exercise; nobody was given MOTS-c. Male mice and male volunteers only. Two authors are consultants and shareholders of CohBar.

    Nature Communications · pubmed.ncbi.nlm.nih.gov

  11. Animal study2019

    MOTS-c inhibits Osteolysis in the Mouse Calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation.

    Treated mice lost markedly less bone, had fewer bone-dissolving cells and less eroded bone surface.

    Full finding, who was studied, and limits

    Who: Adult male mice with plastic wear particles implanted over the skull bone to make the bone dissolve, injected locally once a day for 7 days, plus mouse bone cells in dishes.

    Treated mice lost markedly less bone, had fewer bone-dissolving cells and less eroded bone surface. In dishes, fluid from treated bone cells blocked the formation of bone-dissolving cells, and blocking AMPK undid that.

    Read with care: Mice, a model of bone loss around artificial joints rather than ordinary osteoporosis, short follow-up, and no fracture or bone-strength outcome. Group sizes are not given in the abstract.

    Pharmacological Research · pubmed.ncbi.nlm.nih.gov

  12. Animal study2015

    The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.

    Mice given MOTS-c cleared sugar from the blood faster.

    Full finding, who was studied, and limits

    Who: The paper that first described MOTS-c. Human kidney cells and rat muscle cells in dishes, plus several groups of male mice: 7 mice in a sugar-handling test, 6 to 8 per group in a measurement of insulin action, 10 per group on a high-fat diet for 8 weeks, and 6 per group in a metabolism chamber for 3 weeks. Mice were injected into the abdomen.

    Mice given MOTS-c cleared sugar from the blood faster. In a test that measures how well insulin works, treated mice needed about 30% more sugar infused to keep blood sugar steady, which points to better insulin sensitivity; this came from muscle, as the liver's sugar output did not change. Mice on a high-fat diet for 8 weeks put on less weight than untreated mice while eating the same amount of food, and did not develop the high insulin levels the diet normally causes. In older mice (12 months), muscle that had become insulin resistant responded to insulin like muscle from 3-month-old mice after treatment. The authors also reported that natural MOTS-c levels in mouse muscle and blood fell between 4 and 32 months of age.

    Read with care: Mice and cells, not people. Group sizes are small. The work is from the group that discovered the peptide; two authors disclose that they are consultants for, and shareholders of, CohBar, the company that licensed the peptide. Doses that worked in the short tests and in the long diet study differed tenfold without a clear dose-response being established.

    Cell Metabolism · pmc.ncbi.nlm.nih.gov

  13. Cell study2019

    Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.

    MOTS-c mixed into human blood broke down rapidly into shorter fragments missing their first few amino acids.

    Full finding, who was studied, and limits

    Who: Human blood plasma in the laboratory, used to build and validate an anti-doping test.

    MOTS-c mixed into human blood broke down rapidly into shorter fragments missing their first few amino acids. The authors also found that the antibody test commonly used to measure MOTS-c in blood gave results their mass-spectrometry method could not confirm, and that the two approaches disagreed considerably.

    Read with care: A test tube, not a person, so it does not show how fast MOTS-c disappears in a living body. Its wider importance is the warning that published 'blood MOTS-c levels' from antibody tests may not be measuring what they claim.

    Rapid Communications in Mass Spectrometry · pubmed.ncbi.nlm.nih.gov

  14. Cell study2018

    MOTS-C improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-beta/Smad pathway.

    Treated cells switched on bone-building genes and laid down more calcium deposits.

    Full finding, who was studied, and limits

    Who: Rat bone-marrow stem cells grown in dishes and pushed towards becoming bone cells over 7 days.

    Treated cells switched on bone-building genes and laid down more calcium deposits. Silencing one gene in the TGF-beta signalling pathway cancelled the effect, which the authors take as evidence that the pathway is involved.

    Read with care: Cells in a dish, from rats, with no living animal and no measurement of bone strength. The title says 'improves osteoporosis'; the experiment does not test osteoporosis. The abstract gives no sample sizes or statistics, and the journal is not a leading one.

    European Review for Medical and Pharmacological Sciences · pubmed.ncbi.nlm.nih.gov

Safety findings

  • The central fact: there is no human safety information for MOTS-c. The FDA wrote in May 2026 that it identified no clinical studies or human exposure data for MOTS-c by any route, and that potential safety risks in humans are therefore unknown. Source: fda.gov
  • There is also almost no animal safety information. The FDA found no acute toxicity studies, no repeat-dose toxicity studies, no tests for genetic damage, no reproductive or developmental studies, and no cancer studies for either form of MOTS-c. The animal work that exists was designed to look for benefits, not harms. Source: fda.gov
  • The FDA's own adverse event database (FAERS) was searched for MOTS-c up to 28 February 2024 and again from 26 February 2024 to 9 March 2025. Both searches 'retrieved no reports'. The FDA notes in the same document that pharmacies compounding under section 503A generally do not report adverse events to it, so an empty database does not mean nothing has happened. Source: fda.gov
  • Immune reaction is the FDA's named concern. Because MOTS-c has 16 amino acids, can clump together, and would be injected under the skin, the agency said it 'is concerned about potential for immunogenicity when administered by an injection' and that there are 'insufficient data to conclude that MOTS-c-related BDSs do not present these risks'. This is a risk that could not be ruled out, not an effect seen in patients. Source: fda.gov
4 more safety findings
  • Product quality is a separate problem. The FDA judged both the free base and the acetate 'not well-characterized', because names and CAS numbers in supplier paperwork did not match each other and because the certificates of analysis it found contained no results for impurities, clumping, bacterial endotoxins or microbial contamination, all of which matter for anything injected. Source: fda.gov
  • The nearest thing to human safety data is for a different molecule. In CohBar's announcement of its phase 1a/1b trial of the analogue CB4211, in 65 healthy adults and 20 people with fatty liver, the company said there were no serious adverse events and that injection-site reactions were the only side effect in more than one in ten people. The Department of Health and Human Services cited this analogue trial in 2026 when it said the safety evidence 'points in one direction'. It is an analogue, the numbers are small, the longest exposure was four weeks, and the results were never published in a journal. Source: sec.gov
  • One laboratory finding cuts against the anti-ageing framing. In worn-out (senescent) human skin cells, adding MOTS-c increased the output of inflammatory signalling chemicals including IL-6 and IL-1beta, the pattern that makes senescent cells harmful to surrounding tissue. The authors of a 2018 commentary on this work described mitochondrial-derived peptides as exacerbating senescence rather than reversing it. Source: pubmed.ncbi.nlm.nih.gov
  • Nothing is known about long-term use. No human has knowingly been studied on MOTS-c for any length of time, and no animal study of repeated dosing was designed to look for harm. Source: fda.gov

Rules and status

Not an FDA-approved drug, and not approved in any other country. As of 18 November 2026 it is not on the FDA's list of substances pharmacies may compound from (the section 503A bulks list). Since 30 October 2026 it has been named in a draft enforcement-discretion policy from the U.S. Department of Health and Human Services (HHS), which is not an approval and does not put it on that list.

The full history, with dates

Approval: no product containing MOTS-c is approved by the FDA, and a 2026 FDA review found no monograph in the United States, European or Japanese pharmacopoeias and no product authorised by the European Medicines Agency. Compounding history: MOTS-c (free base) and MOTS-c acetate were placed in 'Category 2' of the FDA's interim compounding policy, the group of nominated substances that 'may present significant safety risks', from 29 September 2023 until 22 April 2026. The only nomination, from Wells Pharmacy Network, was then withdrawn, and MOTS-c moved to FDA's 'nominated but withdrawn' table, where it still sits on the page current as of 22 April 2026. FDA's stated reason on that page is that compounded drugs containing MOTS-c 'may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization'; that 'FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration'; and that 'FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans.' HHS has stated that neither the Category 2 placement nor its removal changed MOTS-c's legal status under section 503A. 2026 advisory meeting: FDA decided to evaluate both forms on its own initiative and published a briefing document dated 11 May 2026 for the Pharmacy Compounding Advisory Committee meeting of 23 and 24 July 2026, where MOTS-c was discussed on 23 July for obesity and osteoporosis. FDA staff proposed NOT adding either form to the 503A list. HHS states that the committee voted in favour of both forms. A committee vote is advice only, and as of 6 August 2026 the FDA meeting page had posted no minutes or vote tallies. The 30 October 2026 notice: HHS published a notice in the Federal Register (91 FR 68526, docket HHS-OASH-2026-0496) announcing a draft 'Enforcement Discretion Policy' for compounding six peptides. MOTS-c is the fourth of the six named in Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026), alongside BPC-157, epitalon, KPV, semax and TB-500. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician who compounds MOTS-c acetate, for injection under the skin or into muscle, when ten conditions are met, including a patient-specific prescription, a single active ingredient, a certificate of analysis from an FDA-registered manufacturer, and reporting of serious side effects to the FDA. HHS's stated justification for MOTS-c is that lot-specific certificates now supply the impurity, residual solvent, endotoxin and microbial results the FDA found missing, that historical use is now documented, and that 'a randomized placebo-controlled trial of a MOTS-c analogue reported no serious adverse events' alongside rodent studies reporting benefit without systemic toxicity. The notice calls the policy a draft and states that it 'does not establish any rights for any person and is not binding on HHS or the public'; the policy text calls itself an interim policy. The comment period ran two weeks from 30 October 2026. The policy applies only until a final rule decides whether each peptide goes on the 503A list; as of 18 November 2026 a Federal Register search found no proposed or final rule adding MOTS-c. None of this is a finding that MOTS-c is safe or effective, and it does not cover products sold for research use only.

Source: govinfo.gov (source dated 2026-10-30)

In sport: Prohibited at all times, in and out of competition. MOTS-c is named in class S4 (Hormone and metabolic modulators), section S4.4.1, as an example of 'Activators of the AMP-activated protein kinase (AMPK)', listed alongside BAM15 and AICAR as 'mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)'. The wording is the same in the 2026 List (in force from 1 January 2026) and the 2027 List (published 21 September 2026, in force from 1 January 2027). The 2026 List states that substances in S4.3 and S4.4 are non-Specified Substances. WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
MOTS-c is 'exercise in a vial' and improves physical performance.In mice, treated old animals ran roughly twice as long on a treadmill as untreated ones. In people, the only exercise finding is the reverse direction: a single hard cycling session raised the body's own MOTS-c in the muscle of 10 young men. No person has been given MOTS-c and tested for performance in any published study. Source: pubmed.ncbi.nlm.nih.gov
MOTS-c extends lifespan.In the one mouse survival experiment, median survival was 6.4% longer and maximum survival 7.0% longer in treated mice, but the difference was not statistically significant overall (P = 0.23) and the authors call it a trend needing larger groups. There is no lifespan evidence in any other species, and none in people. Source: pubmed.ncbi.nlm.nih.gov
It reverses insulin resistance and treats type 2 diabetes.Mice fed a high-fat diet gained less weight and handled sugar better. In people, the evidence is only that blood levels differ between groups, and even that is inconsistent: a 2024 pooled analysis of 602 people found lower levels in type 2 diabetes but higher levels in obesity, and a 20-person study found no difference by weight and more insulin resistance at higher levels. The FDA found no clinical study of MOTS-c for any condition. Source: pmc.ncbi.nlm.nih.gov
It is natural, because your own mitochondria make it, so it must be safe.Being a natural molecule says nothing about the safety of injecting a synthetic copy. The FDA found no human exposure data at all, no animal toxicity studies of any kind, and said that potential safety risks in humans are unknown. It also raised the possibility of an immune reaction to an injected peptide and found certificates of analysis lacking endotoxin and contamination testing. Source: fda.gov
A human trial showed MOTS-c is safe and lowers liver enzymes.That trial tested CB4211, a company-designed analogue of MOTS-c, not MOTS-c. It enrolled 20 people with fatty liver for four weeks, its results were released by the company rather than published, and liver fat itself did not fall more than with placebo. Source: clinicaltrials.gov
Your MOTS-c level can be measured to track how well you are ageing.The commonly used antibody test has not been confirmed by mass spectrometry: an anti-doping laboratory reported that the two methods gave considerably different results in the same samples. Blood and muscle levels also move in opposite directions with age in healthy men. Source: pubmed.ncbi.nlm.nih.gov
The federal government approved MOTS-c in 2026.It is not approved. FDA staff recommended against adding it to the pharmacy compounding list. What exists is a draft HHS policy, published on 30 October 2026, saying HHS does not intend to take enforcement action against licensed pharmacies and physicians who compound it under ten conditions while a rule is worked out. The notice says the policy creates no rights and is not binding. Source: govinfo.gov
It is not a steroid, so it is allowed in sport.It is banned at all times, in and out of competition. The World Anti-Doping Agency names it by its full name in the Prohibited List under S4.4.1 as an example of an AMPK activator. Source: wada-ama.org

What a genuine lab report should show

  • Identity by mass spectrometry: the measured mass should match about 2174.6 g/mol for the free base (formula C101H152N28O22S2). A certificate the FDA reproduced in its 2026 review reported a monoisotopic mass result against that target.
  • The report should confirm the full amino acid sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. The FDA's testing standard for compounded peptides asks for 100% sequence coverage.
  • The report should state plainly which chemical form was tested: the free base or the acetate salt. The FDA found supplier paperwork in which the product name, the CAS number and the certificate referred to different things, and noted there is no separate CAS number for the acetate.
  • Purity by high-performance liquid chromatography (HPLC), with peptide-related impurities named and quantified, not just a single purity percentage. The FDA specifically criticised certificates that gave a purity figure with no impurity limits.
  • A result for clumped peptide (aggregates). The FDA singled this out for MOTS-c because aggregation is a trigger for immune reactions, and said it could not rule that risk out without the data.
  • For anything injectable: bacterial endotoxin testing and microbial bioburden or sterility results. The FDA called these critical and could not find them for either form of MOTS-c.
  • Peptide content, or net peptide, which is how much actual peptide is in the vial. This is a different measurement from purity, and the example certificate in the FDA review reported both.
  • A lot-specific certificate tied to the batch number on the vial, naming the testing laboratory, dated, and identifying the original manufacturer and its physical location. The 2026 HHS policy expects exactly this.

How to read a lab report

What is not known

  • Does MOTS-c do anything in a human being? No clinical study has ever given it to a person, according to the FDA's 2026 search. The first registered trial (NCT07505745) has no results.
  • How much injected MOTS-c would survive in the body, and for how long? No measurement exists in any living animal or person. In a test tube, MOTS-c in human blood broke down quickly.
  • What are the real blood levels? An anti-doping laboratory could not confirm, by mass spectrometry, the levels that the commonly used antibody test reports. Most human observational studies rest on that antibody test, so their numbers may not be comparable.
  • Why do the human observational studies disagree? A pooled analysis found lower levels in type 2 diabetes but higher levels in obesity; one 20-person study found no difference by weight and found higher levels alongside more insulin resistance. Nobody has explained this.
  • Does MOTS-c in muscle rise or fall with age? Blood levels fall in older men while muscle levels appear to rise, which does not fit the simple 'declines with age' story.
  • Is the lifespan claim real? The single mouse survival experiment did not reach statistical significance (P = 0.23) and has not been repeated by an independent group that I could find.
  • Could it be harmful in people with worn-out cells or undetected disease? MOTS-c increased inflammatory output from senescent human cells in one study, and there are no animal cancer or long-term toxicity studies at all.
  • How much of the animal work would hold up independently? A large share of the influential studies comes from the group that discovered the peptide, whose senior members are shareholders in the company that licensed it, and the FDA noted that no study tested whether larger amounts give larger effects.
  • What happened to CB4211? CohBar announced positive phase 1b results in 2021 and said it would present more at a scientific meeting. I found no publication and no later trial. Whether the programme was stopped, and why, is not in any source I could open.
  • When was MOTS-c first named on the WADA Prohibited List? I verified the 2026 and 2027 Lists directly. Anti-doping bodies describe it as added for 2025, and the FDA briefing document says it appeared in a reference database drawing on the 2024 List. I could not open the 2024 or 2025 List PDFs to settle this.
  • Was the discovery in 2012 or 2015? The paper is dated 2015; CohBar's 2021 announcement says 2012. The earlier date presumably refers to unpublished work.
  • Is the HHS policy of 30 October 2026 now final? The Federal Register notice calls it a draft, the policy text calls itself interim, the comment period closed in mid-November 2026, and I found no later notice finalising, changing or withdrawing it.
  • What exactly did the advisory committee vote on 23 July 2026? HHS states the committee voted in favour of both forms of MOTS-c. The FDA meeting page, current as of 6 August 2026, had posted no minutes, transcript or tally.

Sources

All 34 sources
  1. PubChem: MOTS-c, CID 146675088 (formula, weight, CAS, UNII, sequence). pubchem.ncbi.nlm.nih.gov
  2. UniProt A0A0C5B5G6, MOTSC_HUMAN (sequence, gene MT-RNR1, function, K14Q variant). uniprot.org
  3. Lee et al. 2015, Cell Metabolism, discovery of MOTS-c. pmc.ncbi.nlm.nih.gov
  4. Kim et al. 2018, Cell Metabolism, MOTS-c moves to the nucleus. pubmed.ncbi.nlm.nih.gov
  5. Reynolds et al. 2021, Nature Communications, exercise capacity in aged mice and human exercise response. pubmed.ncbi.nlm.nih.gov
  6. Fuku et al. 2015, Aging Cell, the m.1382A>C variant and longevity hypothesis. pubmed.ncbi.nlm.nih.gov
  7. Zempo et al. 2021, Aging, m.1382A>C and type 2 diabetes in 27,527 people. pmc.ncbi.nlm.nih.gov
  8. Du et al. 2018, Pediatric Diabetes, blood MOTS-c in children with obesity. pubmed.ncbi.nlm.nih.gov
  9. Cataldo et al. 2018, Journal of Investigative Medicine, lean versus obese adults. pubmed.ncbi.nlm.nih.gov
  10. D'Souza et al. 2020, Aging, muscle and blood MOTS-c across age groups in men. pubmed.ncbi.nlm.nih.gov
  11. Ramanjaneya et al. 2019, Clinical Endocrinology, lipids, insulin and exercise training. pubmed.ncbi.nlm.nih.gov
  12. Zhou et al. 2024, Diabetology & Metabolic Syndrome, meta-analysis of blood MOTS-c in metabolic disease. pmc.ncbi.nlm.nih.gov
  13. Kumagai et al. 2021, American Journal of Physiology, MOTS-c and myostatin. pubmed.ncbi.nlm.nih.gov
  14. Kim et al. 2018, Aging, mitochondrial peptides in senescent cells. pubmed.ncbi.nlm.nih.gov
  15. Mendelsohn and Larrick 2018, Rejuvenation Research, 'Mitochondrial-Derived Peptides Exacerbate Senescence'. pubmed.ncbi.nlm.nih.gov
  16. Hu and Chen 2018, rat bone marrow stem cells and the TGF-beta pathway. pubmed.ncbi.nlm.nih.gov
  17. Yan et al. 2019, Pharmacological Research, bone loss in the mouse skull. pubmed.ncbi.nlm.nih.gov
  18. Lu et al. 2019, Journal of Molecular Medicine, ovariectomised mice. pubmed.ncbi.nlm.nih.gov
  19. Kim et al. 2019, Physiological Reports, plasma metabolites in obese mice. pubmed.ncbi.nlm.nih.gov
  20. Knoop et al. 2019, anti-doping detection method and breakdown in human blood. pubmed.ncbi.nlm.nih.gov
  21. Miller et al. 2022, Journal of Clinical Investigation, review of mitochondria-derived peptides (states UCLA licensed the IP to CohBar). pubmed.ncbi.nlm.nih.gov
  22. Zheng et al. 2023, Frontiers in Endocrinology, review. pubmed.ncbi.nlm.nih.gov
  23. ClinicalTrials.gov NCT03998514, CB4211 phase 1a/1b, completed 2021, no results posted. clinicaltrials.gov
  24. CohBar press release of 10 August 2021 on CB4211 phase 1a/1b topline results, filed with the SEC as exhibit 99.2 to a Form 8-K. sec.gov
  25. ClinicalTrials.gov NCT07505745, phase 2a MOTS-c in prediabetes, recruiting, no results. clinicaltrials.gov
  26. FDA briefing document on MOTS-c for the 23-24 July 2026 advisory committee, dated 11 May 2026. fda.gov
  27. FDA: bulk drug substances that may present significant safety risks (MOTS-c in the 'nominated but withdrawn' table; page current as of 22 April 2026). fda.gov
  28. FDA: 23-24 July 2026 Pharmacy Compounding Advisory Committee meeting page (agenda lists MOTS-c for obesity and osteoporosis; current as of 6 August 2026). fda.gov
  29. Federal Register, 16 April 2026, 91 FR 20465: advisory committee meeting notice. federalregister.gov
  30. Federal Register, 30 October 2026, 91 FR 68526: HHS draft enforcement discretion policy notice. govinfo.gov
  31. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides; MOTS-c is item 4) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
  32. WADA 2026 Prohibited List (S4.4.1 names MOTS-c as an AMPK activator). wada-ama.org
  33. WADA 2027 Prohibited List with tracked changes (S4.4.1 still names MOTS-c, unchanged). wada-ama.org
  34. WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sent to your email, with a note when a compound page or its legal status changes.

Sign-up link not connected yet.